



Prior Authorization Approval Criteria

Cymbalta (duloxetine)

Generic name:	Duloxetine
Brand name:	Cymbalta
Medication class:	Selective serotonin and norepinephrine reuptake inhibitor (SSNRI)
FDA-approved uses:	Major depressive disorder Diabetic neuropathic pain Generalized anxiety disorder Fibromyalgia
Available dosage form:	20 mg, 30 mg, and 60 mg capsules
Usual dose range:	Total daily dose of 40 mg to 60mg may be administered in one or two doses.
Duration of therapy:	Indefinite
Approximate monthly cost: (based on AWP 2008)	40 mg daily = \$236.25 60 mg daily = \$132.50

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

Major depressive disorder or generalized anxiety disorder:

- Must be 18 years of age or older
- Clinically diagnosed major depressive disorder or generalized anxiety disorder
- Failed or intolerant to 2 generic SSRIs

Diabetic neuropathic pain or fibromyalgia:

- Must be 18 years of age or older
- Clinically diagnosed diabetic neuropathic pain or fibromyalgia
- Failed or intolerant to gabapentin (Neurontin)

Contraindications:

- Known hypersensitivity to duloxetine
- Concomitant use of monoamine oxidase inhibitors (MAOIs)
- Uncontrolled narrow-angle glaucoma due to increased risk of mydriasis

Not approved if:

- Patient has any contraindications to the use of duloxetine.
- Patient does not meet the above stated criteria.

Step therapy requirements: 1 generic SSRI or gabapentin

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 11/15/04

Revised: 6/18/08